Mr. Glover is a co-founder, and Chief Executive Officer, President, and Chairman of ZyVersa. He has multifaceted experience in Fortune 100, start up, and entrepreneurial environments. Mr. Glover was formerly a co-founder of Coherus Biosciences where he was focused on business strategy, partnerships, product development, and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins, as well as Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and divestiture of the business to Merck. As Chief Business Officer he led Insmed’s strategic review process which resulted in the merger of Insmed and Transave. Mr. Glover received his B.S. in Marketing from Illinois State University. He serves on the board of PDS Biotechnology and the Coulter Foundation (University of Miami). Mr. Glover was selected to serve on ZyVersa’s Board of Directors based on his extensive experience in the therapeutics industry, his deep knowledge of ZyVersa, and his ongoing experience as a board member of other life sciences companies.

Ms. Cashmere is ZyVersa’s Chief Commercial Officer. She has more than 25 years’ experience in business planning and execution for biopharmaceutical and medical device companies ranging in size from start-up to Fortune 100 companies. She formerly led the marketing communications function at Mako Surgical Corporation, an emerging robotic orthopedics company. At Mako she was responsible for creating awareness and driving sales of Robotic Arm Systems priced at over $1 million each, and their associated implants for knee and hip arthroplasty. Substantial unit sales and revenue growth during her tenure culminated in a $1.65 billion acquisition by Stryker. Ms. Cashmere also served as Sr. Vice President, New Product Marketing at Auxilium Pharmaceuticals, an emerging pharmaceutical company focused on men’s health and orphan indications. Responsibilities included creation of a new product marketing business unit, strategic opportunity assessment, pipeline prioritization, commercial oversight of clinical development, and masterminding new product commercialization strategies. Ms. Cashmere led Auxilium’s strategic partnership review process, resulting in out-licensing European rights of a key asset with multiple indications, Xiaflex, to Pfizer. Prior to Auxilium, Ms. Cashmere was Sr. Director, Marketing at Andrx Laboratories, responsible for a newly created business unit focusing on commercialization of pipeline products for men’s health. Earlier she held strategic marketing positions at Noven, Serono, and Abbott, now Abbvie.

Mr. Wolfe is ZyVersa’s Chief Financial Officer and Secretary. Mr. Wolfe has spent his career in various financial roles in the financial services, specialty finance, and the pharmaceutical/healthcare industries. Most recently Mr. Wolfe has spent his time cultivating start-up organizations in various healthcare entities, often dealing with complicated business models to develop a financial framework for success for many of these first of their kind businesses. Mr. Wolfe has spent the last 24 years of his career in the healthcare industry with one fourth of that time spent at Kos Pharmaceuticals, a publicly traded, fully-integrated specialty pharmaceutical company. Mr. Wolfe has his BBA from the University of Miami and his MBA from the University of Pittsburgh.